The DOI matches its Crossref record.
CAR-T: trailblazing the path from clinical development to the clinic
Open accessOverview
CoChat Summary
TL;DR
This commentary describes the path of tisagenlecleucel from the Penn/Novartis collaboration to the first FDA approval of a CAR-T therapy in August 2017, emphasizing the manufacturing, supply-chain, and risk-management innovations needed for a personalized “living drug.” It also outlines ongoing CAR-T development across hematologic malignancies and solid tumors.
Key findings
- In August 2017, the FDA granted its first-ever approval of a CAR-T therapy, tisagenlecleucel, for children and young adults with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or has relapsed at least twice.
- Penn’s Carl June and colleagues developed a disabled lentiviral vector approach to genetically encode T cells; Penn published CAR-T results in three patients with leukemia, and Novartis entered a global collaboration with Penn in 2012.
- Delivering tisagenlecleucel required integrated cGMP manufacturing, a global supply chain, a Chain of Identity (COI) system from leukapheresis through infusion, certified treatment centers, and a REMS program to mitigate cytokine release syndrome (CRS) and neurological toxicities.
- The paper reports ongoing investigation of tisagenlecleucel in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL), plus next-generation humanized CD19 CAR-T in chronic lymphocytic leukemia and other CAR-Ts targeting myeloid leukemia, multiple myeloma, glioblastoma, ovarian cancer, lung cancer, and mesothelioma.
Methods
- This is a narrative commentary/perspective by a Novartis employee, not a primary research study; no experimental design, sample, or statistical analysis is reported.
- It describes the development and commercialization of tisagenlecleucel, referencing Penn’s published results in three leukemia patients and the 2012 Novartis-Penn collaboration.
- The main analysis is a descriptive industry account of manufacturing, supply chain, COI, treatment-center certification, and REMS implementation.
Limitations
- The paper states no limitations. It discloses that the author is an employee of and receives compensation from Novartis.
- Evident from the text: it is a single-author industry perspective with no primary data, no systematic methods, and no patient-level outcomes beyond the regulatory approval and the referenced three-patient Penn publication.
- Evident from the text: the author’s Novartis affiliation and compensation create a potential conflict of interest that may shape the emphasis of the commentary.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 0 Not valid · 0 Not checked · 13 Own results and interpretations
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Unlike other therapies, for which the stages from development through commercialization are relatively siloed, the development and commercialization of tisagenlecleucel-a”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Probably not a substantial claim. 10
- It may state two separate claims as one. 5
Citations
Cited by
Development and Clinical Translation of Approved Gene Therapy Products for Genetic Disorders
Shahryari, A., Saghaeian Jazi, M., Mohammadi, S., Razavi Nikoo, H., Nazari, Z., Hosseini, E. S., Burtscher, I., Mowla, S. J., & Lickert, H. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00868 · Cited by 262
“…two cell-based gene therapies for the treatment of acute lymphoblastic leukemia (ALL), Approved Human Gene Therapy ProductsShahryari et al. 2 September 2019 | Volume 10 | Article 868Frontiers in Genetics | www.frontiersin.org were also approved by FDA (Butera, 2018; Vormittag et al., 2018).”
Metadata
- Authors
- Butera, S.
- Affiliations
- Novartis (United States) (US)
- Corresponding author
- Butera, Samuele
- Venue
- Gene Therapy
- Published
- 2018-04-23
- Volume
- 25
- Issue
- 3
- Pages
- 163-164
- ISSN
- 0969-7128 (ISSN-L)
- 1476-5462
- OpenAlex
- W2801365187
- Cited by
- 1
- References
- 0
- Citations by year
- 2019: 1
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Gene Therapy (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- CAR T-cell therapy, chimeric antigen receptor T cells, regulatory approval, clinical development, cancer immunotherapy, clinical translation
- MeSH terms
- Biotechnology, Humans, Receptors, Antigen, T-Cell, Immunotherapy, Adoptive, Drug Delivery Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CAR-T: trailblazing the path from clinical development to the clinic. https://app.cochat.ai/papers/10.1038/s41434-018-0013-z
- The paper
- Butera, S. (2018). CAR-T: trailblazing the path from clinical development to the clinic. Gene Therapy. https://doi.org/10.1038/s41434-018-0013-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.